Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Republic of Korea.
Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
BMC Cancer. 2020 Mar 4;20(1):185. doi: 10.1186/s12885-020-6688-8.
To analyze the effects of BRCA1/2 mutations on chemotherapy response scores (CRS) and survival in a cohort of patients with advanced-stage ovarian cancer who were treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS).
We retrospectively reviewed the medical records of 169 high-grade serous ovarian cancer patients who underwent a germline BRCA1/2 test and received three cycles of NAC at the Yonsei Cancer Center from 2006 to 2018. Chemotherapy response scores were compared in patients with and without BRCA1/2 mutations. The effects of BRCA1/2 mutations and CRS on survival were evaluated.
BRCA1/2 mutations were detected in 47 (28.1%) of the 169 patients. Overall, 16 (34.0%) patients with BRCA1/2 mutations had a CRS 3 to chemotherapy compared to scores of 43 in patients (35.2%) without a mutation. Response scores of 3 in patients with BRCA1/2 mutations were not significantly associated with either improved progression-free survival (PFS) (P = 0.949) or overall survival (OS) (P = 0.168). However, CRS 3 in patients without BRCA mutations was significantly associated with both improved PFS (P = 0.030) and OS (P = 0.039). In patients with CRS1/2, carriers of BRCA1/2 mutations had better PFS (P = 0.0344) and OS (P = 0.043) than wild-type BRCA genotype patients.
In ovarian cancer patients treated with NAC, CRS did not predict survival for BRCA 1/2 mutation carriers but did for BRCA wild-type patients.
分析 BRCA1/2 突变对接受新辅助化疗（NAC）后行间隔减瘤术（IDS）的晚期卵巢癌患者化疗反应评分（CRS）和生存的影响。
我们回顾性分析了 2006 年至 2018 年在延世癌症中心接受 BRCA1/2 种系检测并接受 3 个周期 NAC 的 169 例高级别浆液性卵巢癌患者的病历。比较了有和无 BRCA1/2 突变患者的化疗反应评分。评估了 BRCA1/2 突变和 CRS 对生存的影响。
在 169 例患者中，检测到 BRCA1/2 突变 47 例（28.1%）。总体而言，16 例（34.0%）有 BRCA1/2 突变的患者的 CRS 为 3-化疗，而无突变的患者的 CRS 为 43。BRCA1/2 突变患者的 CRS 为 3 与无突变患者的无进展生存期（PFS）（P=0.949）或总生存期（OS）（P=0.168）均无显著相关性。然而，无 BRCA 突变患者的 CRS 为 3 与改善 PFS（P=0.030）和 OS（P=0.039）显著相关。在 CRS1/2 患者中，BRCA1/2 突变携带者的 PFS（P=0.0344）和 OS（P=0.043）均优于野生型 BRCA 基因型患者。
在接受 NAC 的卵巢癌患者中，CRS 不能预测 BRCA1/2 突变携带者的生存，但能预测 BRCA 野生型患者的生存。
